Abstract
Since more than one decade, metabotropic glutamate receptors have been under investigation as targets for various CNS disorders such as anxiety, pain, depression, schizophrenia, Alzheimers disease and Parkinsons disease. It has been shown that some mGluRs play a crucial role in cognitive processes such as learning and memory, which was initially, demonstrated using knockout mice for each receptor subtype. Later, selective pharmacological tools were developed allowing more specific examinations of the involvement of mGluR1-8 in various forms of learning and memory. Ligands for group I and II mGluRs have been proposed as promising candidates for the treatment of cognitive disorders such as schizophrenia, Fragile X syndrome, Alzheimers and Parkinsons disease and posttraumatic stress disorder, of which some have made it to clinical testing. The present paper reviews relevant data on the role of mGluRs in learning and cognition processes focusing on their utility as targets for cognition enhancement in several CNS diseases.
Keywords: mGluR, learning, metabotropic glutamate receptors, cognition
Current Topics in Medicinal Chemistry
Title: Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
Volume: 10 Issue: 2
Author(s): A. Gravius, M. Pietraszek, A. Dekundy and W. Danysz
Affiliation:
Keywords: mGluR, learning, metabotropic glutamate receptors, cognition
Abstract: Since more than one decade, metabotropic glutamate receptors have been under investigation as targets for various CNS disorders such as anxiety, pain, depression, schizophrenia, Alzheimers disease and Parkinsons disease. It has been shown that some mGluRs play a crucial role in cognitive processes such as learning and memory, which was initially, demonstrated using knockout mice for each receptor subtype. Later, selective pharmacological tools were developed allowing more specific examinations of the involvement of mGluR1-8 in various forms of learning and memory. Ligands for group I and II mGluRs have been proposed as promising candidates for the treatment of cognitive disorders such as schizophrenia, Fragile X syndrome, Alzheimers and Parkinsons disease and posttraumatic stress disorder, of which some have made it to clinical testing. The present paper reviews relevant data on the role of mGluRs in learning and cognition processes focusing on their utility as targets for cognition enhancement in several CNS diseases.
Export Options
About this article
Cite this article as:
Gravius A., Pietraszek M., Dekundy A. and Danysz W., Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders, Current Topics in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/156802610790411018
DOI https://dx.doi.org/10.2174/156802610790411018 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy EDITORIAL [Hot Topic Recognition of Functional Roles of Free Radicals Guest Editor: István Bokkon]
Current Neuropharmacology Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists
Current Medicinal Chemistry Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Clozapine Safety, 40 Years Later
Current Drug Safety Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
CNS & Neurological Disorders - Drug Targets Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Targeted D4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development
Current Drug Targets 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews A Laconic Overview on Fast Dissolving Sublingual Films as Propitious Dosage Form
Drug Delivery Letters Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry